Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor
Bioorganic Chemistry · 2024
DOI: 10.1016/j.bioorg.2024.107352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024. Verfasst von Chunwei Mo und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharma…. Hauptthemen laut MEDLINE: Fluorine Radioisotopes, Glypicans, Positron-Emission Tomography. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Ministry of Science and Technology of the People's Republic of China.
Abstract (Originalsprache)
Glypican-3 (GPC3) is markedly overexpressed in hepatocellular carcinoma (HCC) and not expressed in normal liver tissues. In this study, a novel peptide PET imaging agent ([18F]AlF-NOTA-IPB-GPC3P) was developed to target GPC3 expressed in tumors. The overall radiochemical yield of [18F]AlF-NOTA-IPB-GPC3P was 10-15 %, and its lipophilicity, expressed as the logD value at a pH of 7.4, was -1.18 ± 0.06 (n = 3). Compared to the previously reported tracer [18F]AlF-GP2633, [18F]AlF-NOTA-IPB-GPC3P exhibited higher cellular uptake (15.13 vs 5.96) and internalized rate (80.63 % vs 35.93 %) in Huh7 cells at 120 min. Micro-PET/CT and biodistribution studies further demonstrated that [18F]AlF-NOTA-IPB-GPC3P exhibited significantly increased tumor uptake and prolonged tumor residence in Huh7 tumors compared to [18F]AlF-GP2633 (4.66 ± 0.22 % ID/g vs 0.72 ± 0.09 % ID/g at 60 min, p < 0.001; 5.05 ± 0.23 % ID/g vs 0.35 ± 0.08 % ID/g at 120 min, p < 0.001, respectively). Furthermore, the tumor-to-organ ratios of [18F]AlF-NOTA-IPB-GPC3P surpassed those of [18F]AlF-GP2633. Our results support the utilization of [18F]AlF-NOTA-IPB-GPC3P as a PET imaging agent targeting the GPC3 receptor for tumor detection.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou, Guangdong Province 510515, China.
- Department of Nuclear Medicine, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan 523059, China. Electronic address: shunhuang007@163.com.
- Department of Nuclear Medicine, Nanfang Hospital, Southern Medical University, GDMPA Key Laboratory for Quality Control and Evaluation of Radiopharmaceuticals, Guangzhou, Guangdong Province 510515, China. Electronic add…
Förderung
- National Natural Science Foundation of China
- Ministry of Science and Technology of the People's Republic of China
Zitieren
APA
Mo, C., Sun, P., Liang, H., Chen, Z., Wang, M., Fu, L., Huang, S., & Tang, G. (2024). Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2024.107352
Vancouver
Mo C, Sun P, Liang H, Chen Z, Wang M, Fu L, et al. Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor. Bioorganic Chemistry. 2024. doi:10.1016/j.bioorg.2024.107352
BibTeX
@article{Mo2024,
author = {Mo, Chunwei and Sun, Penghui and Liang, Haoran and Chen, Zihao and Wang, Meng and Fu, Lilan and Huang, Shun and Tang, Ganghua},
title = {Synthesis and preclinical evaluation of a novel probe [18F]AlF-NOTA-IPB-GPC3P for PET imaging of GPC3 positive tumor},
journal = {Bioorganic Chemistry},
year = {2024},
doi = {10.1016/j.bioorg.2024.107352}
}
EUVIMED